Early research hints that GLP-1 receptor agonists may reduce sleep apnea severity, but the evidence is still too weak and conflicting to draw firm conclusions.
9 studies reviewedOnly nine studies were found examining GLP-1 drugs for sleep apnea, and the overall evidence quality was rated low — highlighting how early this research area still is.
What the researchers found
Across nine included studies, there was early evidence suggesting GLP-1 receptor agonists may improve obstructive sleep apnea as measured by reductions in the apnoea-hypopnoea index (AHI). However, this finding was not consistent — some studies showed contradictory results.
Of the nine articles, five were randomized clinical trials of variable quality, one was a non-randomized trial, one was a case report, one was a study protocol, and one was an RCT abstract. All studies examined GLP-1RA use in patients with diagnosed OSA or suggestive symptoms. The medications were generally well tolerated, with only minor gastrointestinal side effects reported.
Why it matters
Sleep apnea affects millions of people worldwide and is typically managed with CPAP machines, which many patients find uncomfortable and difficult to use consistently. If GLP-1 receptor agonists — already proven effective for weight loss and blood sugar control — could also treat sleep apnea, it would offer a more convenient pharmaceutical alternative. However, this review shows the science isn't there yet, tempering the market hype that has already driven major investment shifts away from traditional sleep apnea treatments.
How the study worked
The researchers conducted a scoping review by searching three major medical databases — Medline, Embase, and Cochrane Central. They included any papers that evaluated GLP-1 receptor agonist medications in relation to sleep-disordered breathing, obstructive sleep apnea, or related conditions. Nine articles met the inclusion criteria and were analyzed.
What this study cannot tell us
The quality of evidence across all included studies was low. Follow-up periods were too short to assess whether any improvements in sleep apnea would be durable over time. The study pool was small at just nine articles, and the study designs varied widely — from case reports to randomized trials — making it difficult to draw strong conclusions. Results across studies were also conflicting, with some showing benefit and others not.
How to read the evidence
This is a scoping review that synthesized findings from nine studies of variable quality. The included studies were mostly small, had short follow-up periods, and produced conflicting results. The overall evidence quality is low, meaning conclusions should be considered preliminary.
When this study was published
Published in 2024, this review captures the current state of a rapidly evolving research area. Given the surge of interest in GLP-1 receptor agonists, newer and larger clinical trials are likely underway or recently completed.
The bigger picture
GLP-1 receptor agonists like semaglutide and liraglutide are reshaping treatment paradigms across multiple conditions beyond their original diabetes indication. The connection between weight loss and sleep apnea improvement is biologically plausible, since excess weight is a primary risk factor for OSA. This review captures a critical moment where investment enthusiasm has outpaced the clinical evidence, highlighting the gap between market sentiment and proven medical benefit.
Questions still open
- Do GLP-1 receptor agonists improve sleep apnea through weight loss alone, or is there a direct mechanism affecting airway function?
- How long do patients need to take GLP-1 drugs before seeing meaningful improvements in sleep apnea severity?
- Could combining GLP-1 receptor agonists with CPAP therapy produce better outcomes than either treatment alone?
Common questions
Can GLP-1 drugs like Ozempic or Wegovy cure sleep apnea?
Should I stop using my CPAP machine if I start taking a GLP-1 medication?
Read the original research
The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.
Pharmacy (Basel, Switzerland), 12(1)
Citation
Le, Khang Duy Ricky; Le, Kelvin; Foo, Felicia. (2024). The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.. Pharmacy (Basel, Switzerland), 12(1). https://doi.org/10.3390/pharmacy12010011